Current and Novel Therapeutic Molecules for Treatment of Neuroinflammation-Mediated Neurodegenerative Disorders
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 2352
Special Issue Editor
Interests: neuroinflammation; oxidative stress; neurodegenerative disease; signalling pathways; nutraceutics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Neuroinflammation is a defense mechanism that initially can have beneficial effects for the central nervous system (CNS), by removing or inhibiting diverse pathogens or cellular debris and promoting tissue repair. Sustained inflammatory responses, however, are detrimental, and they inhibit regeneration. Interestingly, neuroinflammation is emerging as a common feature to target in most CNS pathologies. Neuroinflammation is associated with various neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and others. The lack of effective treatments for most neurodegenerative diseases has prompted the search for novel therapeutic options.
Recent studies suggest the effectiveness of targeted delivery of small molecules to reduce neuroinflammation. A factor limiting the effectiveness of many pharmacological treatments is represented by the blood brain barrier which can lead to the suboptimal action of drugs in the CNS because the neurotherapeutic compounds are currently administered systemically without spatial or temporal control. Emerging technologies of new molecules, such as nanomaterials or small molecules, are providing promising tools to effectively access the brain in a targeted and controlled manner.
This special issue aims to collect current therapeutic options that have a significant impact in the treatment of inflammatory-based neurodegenerative diseases. A further goal is to review emerging therapies in clinical development, including agents that interfere with pathological processes deemed important for neurodegeneration or that aim to enhance reparative and neuroprotective responses. Finally, attention is paid to those studies aimed at identifying therapeutic drugs, small molecules and biological products that can modulate and control neuroinflammation.
Prof. Dr. Maria Antonietta Panaro
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- brain
- neuroinflammation
- neurodegeneration
- small-molecule therapeutics
- bioactive compounds
- natural products
- drug development
